Search Result

Results for "

Chronic hepatitis B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (48) HCV (4) Atg8/LC3 (2) Autophagy (2) Biochemical Assay Reagents (1) CCR (1) Claudin (1) Cytochrome P450 (3) DNA/RNA Synthesis (6) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (3) HCV Protease (3) HIV (13) IFNAR (3) Interleukin Related (1) JAK (1) P-glycoprotein (2) p62 (2) PD-1/PD-L1 (2) Reactive Oxygen Species (ROS) (1) Reference Standards (7) Reverse Transcriptase (11) Small Interfering RNA (siRNA) (2) STAT (1) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (2) Infection (58) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (3) CpG ODNs (1) siRNA drugs (3) Antisense Oligonucleotides (2) Cytidine (2) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13910

Tenofovir Maximum Cited Publications 10 Publications Verification GS 1278; PMPA	Reverse Transcriptase HIV HBV	Infection Neurological Disease Cancer
Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .

HY-13782

Tenofovir Disoproxil fumarate Maximum Cited Publications 10 Publications Verification Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate	HIV Reverse Transcriptase HBV	Infection
Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.

HY-109168

Bersacapavir 2 Publications Verification JNJ-6379; JNJ-56136379	HBV DNA/RNA Synthesis	Infection
Bersacapavir (JNJ-6379) is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .

HY-W018791

Bifendate 2 Publications Verification DDB	HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-13910A

Tenofovir hydrate Maximum Cited Publications 10 Publications Verification GS 1278 hydrate; PMPA hydrate	HIV Reverse Transcriptase	Infection Cancer
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

HY-13782A

Tenofovir Disoproxil Maximum Cited Publications 10 Publications Verification Bis(POC)-PMPA; GS 4331	HIV Reverse Transcriptase HBV	Cancer
Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-N0444

Rubiadin	Reactive Oxygen Species (ROS)	Inflammation/Immunology
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-177022

ALG-001075	HBV	Infection
ALG-001075, a capsid assembly modulator (CAM), is an orally active HBV inhibitor. ALG-001075 effectively blocks not only HBV DNA production but also extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. ALG-001075 shows pronounced reductions of circulating HBV DNA in the AAV-HBV mouse model. ALG-001075 can be used for the study of Chronic hepatitis B (CHB) .

HY-148348

AB-836	HBV	Infection
AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein. AB-836 can be used in research related to chronic hepatitis B .

HY-124600

NVR 3-778 3 Publications Verification	HBV	Infection
NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .

HY-13782R

Tenofovir Disoproxil fumarate (Standard) Tenofovir DF (Standard); Bis(POC)-PMPA fumarate (Standard); GS 4331 fumarate (Standard)	Reference Standards HIV Reverse Transcriptase HBV	Infection
Tenofovir Disoproxil (fumarate) (Standard) is the analytical standard of Tenofovir Disoproxil (fumarate). This product is intended for research and analytical applications. Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.

HY-W074930

(S)-Tenofovir (S)-GS 1278; (S)-PMPA; (S)-TDF	HIV HBV	Infection
(S)-Tenofovir is the less active S-enantiomer of Tenofovir (HY-13910). Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV). (S)-Tenofovir has low activity to Orf virus. (S)-Tenofovir can be used for research on contagious pustular dermatitis .

HY-169993

ALG-000184	HBV DNA/RNA Synthesis Drug Intermediate	Infection
ALG-000184 is an orally effective inhibitor of hepatitis B virus (HBV), and it is also a prodrug of ALG-001075 (HY-177022). ALG-000184 can inhibit the production of HBV DNA in liver cells. ALG-000184 can be used in the research of chronic hepatitis B .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-147255

Canocapavir ZM-H1505R	HBV	Infection
Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .

HY-145638A

Xalnesiran sodium RO7445482 sodium	HBV	Infection
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .

HY-113904S

(Rac)-Tenofovir-d6	Reverse Transcriptase HIV HBV	Infection
(Rac)-Tenofovir-d₆ is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .

HY-137453

Tenofovir amibufenamide 1 Publications Verification HS-10234	HBV	Infection
Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study .

HY-147266

Elebsiran sodium VIR-2218 sodium	Small Interfering RNA (siRNA) HBV	Infection
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-128854

Dimethyl biphenyl-4,4'-dicarboxylate 1 Publications Verification	Biochemical Assay Reagents JAK STAT IFNAR DNA/RNA Synthesis HBV	Infection Metabolic Disease
Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B .\n

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-W352344

2'-Deoxy-L-adenosine	HBV	Infection
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .

HY-114314

BA-53038B	HBV	Infection
BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly. BA-53038B has antiviral activity for hepatitis B virus (HBV) with an EC₅₀ value of 3.32 μM. BA-53038B can be used for the research of chronic hepatitis B .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-103487

Uprifosbuvir IDX21437; MK-3682	HCV	Infection
Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus .

HY-121513

Torcitabine 2'-Deoxy-L-cytidine; L-dC	HBV	Infection
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment .

HY-149158

CCC-0975	HBV	Inflammation/Immunology
CCC-0975 is a hepatitis B virus (HBV) inhibitor (EC₅₀=10 μM). CCC-0975 interferes with the conversion of relaxed circular DNA (rcDNA) to cccDNA, synchronously reducing cccDNA and its precursor deproteinized rcDNA (DP-rcDNA) without promoting their intracellular degradation. CCC-0975 is promising for research of chronic hepatitis B .

HY-147266A

Elebsiran VIR-2218	HBV Small Interfering RNA (siRNA)	Infection
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .

HY-P4051

HBV Seq1 aa:141-151	HBV	Infection Inflammation/Immunology
HBV Seq1 aa:141-151 is a peptide. HBV Seq1 aa:141-151 can be used for the research of chronic hepatitis B virus (HBV) .

HY-P991112

Anti-Mouse CD8α Antibody (YTS169.4)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 ⁺ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-113586

Besifovir Dipivoxil LB-80380	HBV DNA/RNA Synthesis Drug Derivative	Infection
Besifovir Dipivoxil (LB-80380), an analog of guanosine monophosphate, is an acyclic nucleotide phosphonate with antiviral effect. Besifovir Dipivoxil is rapidly converted by the liver and intestine to the intermediate metabolite LB80331 via the esterification process, subsequently phosphorylated into the di- and triphosphate forms, which act as antiviral DNA synthesis inhibitors. Besifovir Dipivoxil is promising for research of chronic hepatitis B .

HY-145638

Xalnesiran RO7445482	HBV	Infection
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

HY-13910R

Tenofovir (Standard) GS 1278 (Standard); PMPA (Standard)	Reference Standards Reverse Transcriptase HIV HBV	Infection Cancer
Tenofovir (Standard) is the analytical standard of Tenofovir. This product is intended for research and analytical applications. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .

HY-W018791R

Bifendate (Standard) DDB (Standard)	Reference Standards HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-13910B

Tenofovir maleate GS 1278 maleate; PMPA maleate	HIV Reverse Transcriptase	Infection Cancer
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

HY-19447A

Besifovir Dipivoxil maleate LB80380 maleate	HBV	Infection
Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies ^[2]

HY-145638X

GalNAc unconjugated/naked Xalnesiran GalNAc unconjugated/naked RO7445482	HBV	Infection
GalNAc unconjugated/naked Xalnesiran is a non-GalNAc-conjugated Xalnesiran (HY-145638). Xalnesiran is siRNA for the study of chronic hepatitis B (HBV) .

HY-177620

Cadapersen RG6084; RO-7191863	PD-1/PD-L1	Cancer
Cadapersen (RG6084) is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).

HY-13910AR

Tenofovir hydrate (Standard) GS 1278 hydrate (Standard); PMPA hydrate (Standard)	Reference Standards HIV Reverse Transcriptase	Infection
Tenofovir (hydrate) (Standard) is the analytical standard of Tenofovir (hydrate). This product is intended for research and analytical applications. Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

HY-136111

KR-26556	HBV	Infection
KR-26556 is a sulfonamide type hepatitis B virus (HBV) capsid assembly regulator. KR-26556 exhibits anti-HBV activity with an EC₅₀ of 0.04 μM. KR-26556 has favorable safety characteristics. KR-26556 can be used for research on chronic hepatitis B .

HY-13782AR

Tenofovir Disoproxil (Standard) Bis(POC)-PMPA (Standard); GS 4331 (Standard)	HIV Reverse Transcriptase HBV Reference Standards	Cancer
Tenofovir Disoproxil (Standard) is the analytical standard of Tenofovir Disoproxil. This product is intended for research and analytical applications. Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

HY-106235

LB80317	HBV DNA/RNA Synthesis	Infection
LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC₅₀ of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment .

HY-115430

Tenofovir disoproxil aspartate	HIV Reverse Transcriptase HBV	Infection
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B .

HY-148768

AB-506	HBV	Inflammation/Immunology
AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .

HY-177300

TLR7/8 agonist 13	Toll-like Receptor (TLR) HBV IFNAR Interleukin Related	Infection Inflammation/Immunology
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .

HY-124600R

NVR 3-778 (Standard)	HBV	Infection
NVR 3-778 (Standard) is the analytical standard of NVR 3-778. This product is intended for research and analytical applications. NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .

HY-162795

HBV-IN-47	HBV	Infection
HBV-IN-47 (compound 4a) is a capsid assembly regulator with inhibitory activity against hepatitis B virus (HBV). HBV-IN-47 exhibits strong anti-HBV activity in HepAD38 cells with low toxicity (EC₅₀=0.24 μM). HBV-IN-47 can be used for the study of chronic hepatitis B (CHB) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-P991112

Anti-Mouse CD8α Antibody (YTS169.4)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 ⁺ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

HY-P992458

SBT8230	Toll-like Receptor (TLR) HBV	Infection
SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001) .

HY-108839

Peginterferon alfa-2a Ro 25-8310/000	IFNAR	Infection
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0444

Rubiadin	Quinones Structural Classification Classification of Application Fields Anthraquinones Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

Cat. No.	Product Name	Chemical Structure

HY-113904S

(Rac)-Tenofovir-d6
(Rac)-Tenofovir-d₆ is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .

Cat. No.	Product Name		Classification

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101		CpG ODNs
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-145638A

Xalnesiran sodium RO7445482 sodium		siRNAs siRNA drugs
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .

HY-147266

Elebsiran sodium VIR-2218 sodium		siRNAs siRNA drugs
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-W352344

2'-Deoxy-L-adenosine		Nucleoside Analogs Adenosine
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .

HY-121513

Torcitabine 2'-Deoxy-L-cytidine; L-dC		Nucleoside Analogs Cytidine
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment .

HY-145638

Xalnesiran RO7445482		siRNAs siRNA drugs
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .

HY-177620

Cadapersen RG6084; RO-7191863		Antisense Oligonucleotides
Cadapersen (RG6084) is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).

HY-W105601

5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine		Nucleoside Analogs Cytidine
5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine) is an antiviral compound that inhibits HBV reverse transcriptase activity. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine shows potential to control HBV replication in vitro. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine, as a nucleoside analog, may provide a new option for the suppression of chronic hepatitis B .

HY-177620A

Cadapersen sodium RG6084 sodium; RO-7191863 sodium		Antisense Oligonucleotides
Cadapersen sodium is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Chronic hepatitis B

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products